2-(2,4-二甲基苯基)喹啉-4-羧酸 | 5466-33-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-(2,4-二甲基苯基)喹啉-4-羧酸
• 中文别名: 2-(2,4-二甲基-苯基)-喹啉-4-羧酸
• 英文名称: 2-(2,4-Dimethyl-phenyl)-chinolin-4-carbonsaeure
• 英文别名: 2-(2,4-Dimethylphenyl)quinoline-4-carboxylic acid
• CAS: 5466-33-1
• 化学式: C₁₈H₁₅NO₂
• mdl: MFCD00687594
• 分子量: 277.323
• InChiKey: LQOCMAVPLYTGBG-UHFFFAOYSA-N

物化性质

• 熔点：
  218 °C
• 沸点：
  454.8±33.0 °C(Predicted)
• 密度：
  1.220±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  2-(2,4-二甲基苯基)喹啉-4-羧酸 在 吡啶 、 氯化亚砜 作用下， 生成 2-(2,4-dimethylphenyl)-N-[4-(pyrimidin-2-ylsulfamoyl)phenyl]quinoline-4-carboxamide
  参考文献：
  名称：

  Discovering novel chemical inhibitors of human cyclophilin A: Virtual screening, synthesis, and bioassay

  摘要：

  Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA). CypA plays critical roles in various biological processes, including protein folding, assembly, transportation, regulation of neuron growth, and HIV replication. The discovery of CypA inhibitor is now of a great special interest in the treatment of immunological disorders. In this study, a series of novel small molecular CypA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. The SPECS-1 database containing 85,000 small molecular compounds was searched by virtual screening against the crystal structure of human CypA. After SPR-based binding affinity assay, 15 compounds were found to show binding affinities to CypA at submicro-molar or micromolar level (compounds 1-15). Seven compounds were selected as the starting point for the further structure modification in considering binding activity, synthesis difficulty, and structure similarity. We thus synthesized 40 new small molecular compounds (1-6, 15, 16a-q, 17a-d, and 18a-I), and four of which (compounds 16b, 16h 16k,. and 18g) showed high CypA PPIase inhibition activities with IC50S of 2.5-6,2 mu M. Pharmacological assay indicated that these four Compounds demonstrated somewhat inhibition activities against the proliferation of spleen cells. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.11.006
• 作为产物：
  描述：

  靛红 、 2,4-二甲基苯乙酮 生成 2-(2,4-二甲基苯基)喹啉-4-羧酸
  参考文献：
  名称：

  Quinoline-4-carbonylguanidine derivatives, process for producing the

  摘要：

  本发明涉及由式（1）所代表的喹啉-4-羰基胍衍生物及其药学上可接受的盐，制备该化合物的方法，以及含有该化合物作为活性成分的Na.sup.+ /H.sup.+交换抑制剂。本发明的化合物可用作治疗或预防由Na.sup.+ /H.sup.+交换器的高功能引起的各种疾病的药剂，以及用于这些疾病的诊断剂。

  公开号：

  US05627193A1

文献信息

• Quinoline-4-carbonylguanidine derivatives, process for producing the
  申请人：Mitsui Toatsu Chemicals, Inc.

  公开号：US05627193A1

  公开（公告）日：1997-05-06

  The present invention relates to quinoline-4-carbonylguanidine derivative represented by formula (1) ##STR1## and pharmaceutically acceptable salt thereof, a process for producing the same, and a Na.sup.+ /H.sup.+ exchanger inhibitor containing the compound as an active ingredient. The compounds of the present invention are useful as an agent for treating or preventing various diseases by hyperfunction of the Na.sup.+ /H.sup.+ exchanger and as a diagnostic agent for these diseases.

  本发明涉及由式（1）所代表的喹啉-4-羰基胍衍生物及其药学上可接受的盐，制备该化合物的方法，以及含有该化合物作为活性成分的Na.sup.+ /H.sup.+交换抑制剂。本发明的化合物可用作治疗或预防由Na.sup.+ /H.sup.+交换器的高功能引起的各种疾病的药剂，以及用于这些疾病的诊断剂。
• Buu-Hoi; Cagniant, Bulletin de la Societe Chimique de France, 1946, p. 123,130
  作者：Buu-Hoi、Cagniant

  DOI：——

  日期：——
• Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0726254B1

  公开（公告）日：1998-05-06
• LIGANDS THAT TARGET HCV-E2 BINDING SITES ON CD81 AND THERAPEUTIC METHODS USING THEM
  申请人：American University of Cairo

  公开号：US20150328329A1

  公开（公告）日：2015-11-19

  Ligands that target the HCV-E2 binding site and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of E2 binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds. Identification and design of groups of compounds that bind to CD81 for use as therapeutics for treating patients infected by Hepatitis C virus and other viruses that interact with CD81. By binding to CD81, these molecules can block 1) HCV and other viral entry into cells (infection), 2) inflammatory responses caused by HCV and other viral infections, and 3) the induction of HCV associated cancers.
• US5627193A
  申请人：——

  公开号：US5627193A

  公开（公告）日：1997-05-06